{ "labelLang" : "hun", "responseDate" : "2024-03-28 13:40", "content" : { "otype" : "BookChapter", "mtid" : 26974257, "status" : "APPROVED", "published" : true, "unhandledTickets" : 0, "oldTimestamp" : "2017-11-23T07:40:45.000+0000", "deleted" : false, "oldId" : 16974257, "lastRefresh" : "2024-02-27T13:38:42.999+0000", "lastModified" : "2024-02-27T13:07:11.189+0000", "created" : "2017-11-21T09:35:08.000+0000", "creator" : { "otype" : "Admin", "mtid" : 10060827, "link" : "/api/admin/10060827", "label" : "Zeller Rozália (SZTE admin5)", "familyName" : "Zeller", "givenName" : "Rozália", "published" : true, "oldId" : 10060827, "snippet" : true }, "lastDuplumOK" : "2024-02-27T13:07:11.541+0000", "lastDuplumSearch" : "2024-02-27T13:07:11.541+0000", "core" : false, "citation" : true, "publicationPending" : false, "type" : { "otype" : "PublicationType", "mtid" : 25, "link" : "/api/publicationtype/25", "label" : "Könyvrészlet", "code" : 25, "otypeName" : "BookChapter", "listPosition" : 2, "published" : true, "oldId" : 25, "snippet" : true }, "subType" : { "otype" : "SubType", "mtid" : 10000398, "link" : "/api/subtype/10000398", "label" : "Könyvfejezet (Könyvrészlet)", "name" : "Könyvfejezet", "nameEng" : "Chapter", "docType" : { "otype" : "PublicationType", "mtid" : 25, "link" : "/api/publicationtype/25", "label" : "Könyvrészlet", "code" : 25, "otypeName" : "BookChapter", "listPosition" : 2, "published" : true, "oldId" : 25, "snippet" : true }, "listPosition" : 220, "published" : true, "oldId" : 10000398, "snippet" : true }, "category" : { "otype" : "Category", "mtid" : 1, "link" : "/api/category/1", "label" : "Tudományos", "published" : true, "oldId" : 1, "snippet" : true }, "languages" : [ { "otype" : "Language", "mtid" : 10002, "link" : "/api/language/10002", "label" : "Angol", "name" : "Angol", "nameEng" : "English", "published" : true, "oldId" : 2, "snippet" : true } ], "firstAuthor" : "Adeniji, AO", "authorships" : [ { "otype" : "PersonAuthorship", "mtid" : 73465400, "link" : "/api/authorship/73465400", "label" : "Adeniji, AO", "listPosition" : 1, "share" : 0.0, "first" : true, "last" : false, "familyName" : "Adeniji", "givenName" : "AO", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "oldId" : 149386478, "snippet" : true }, { "otype" : "PersonAuthorship", "mtid" : 73465401, "link" : "/api/authorship/73465401", "label" : "Adams, PW", "listPosition" : 2, "share" : 0.0, "first" : false, "last" : false, "familyName" : "Adams", "givenName" : "PW", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "oldId" : 149386477, "snippet" : true }, { "otype" : "PersonAuthorship", "mtid" : 73465402, "link" : "/api/authorship/73465402", "label" : "Mody, VV", "listPosition" : 3, "share" : 0.0, "first" : false, "last" : true, "familyName" : "Mody", "givenName" : "VV", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "oldId" : 149386476, "snippet" : true } ], "title" : "Amyloid - Hypothesis in the Development of Therapeutic Agents for Alzheimer's Disease", "identifiers" : [ { "otype" : "PublicationIdentifier", "mtid" : 13234602, "link" : "/api/publicationidentifier/13234602", "label" : "DOI: 10.1016/B978-0-12-802810-0.00007-6", "source" : { "otype" : "PlainSource", "mtid" : 6, "link" : "/api/publicationsource/6", "label" : "DOI", "type" : { "otype" : "PublicationSourceType", "mtid" : 10001, "link" : "/api/publicationsourcetype/10001", "label" : "DOI", "mayHaveOa" : true, "published" : true, "snippet" : true }, "name" : "DOI", "nameEng" : "DOI", "linkPattern" : "https://doi.org/@@@", "publiclyVisible" : true, "published" : true, "oldId" : 6, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "10.1016/B978-0-12-802810-0.00007-6", "realUrl" : "https://doi.org/10.1016/B978-0-12-802810-0.00007-6", "published" : false, "oldId" : 16042918, "snippet" : true }, { "otype" : "PublicationIdentifier", "mtid" : 16859738, "link" : "/api/publicationidentifier/16859738", "label" : "WoS: 000413005100009", "source" : { "otype" : "PlainSource", "mtid" : 1, "link" : "/api/publicationsource/1", "label" : "WoS", "type" : { "otype" : "PublicationSourceType", "mtid" : 10003, "link" : "/api/publicationsourcetype/10003", "label" : "Indexelő adatbázis", "mayHaveOa" : false, "published" : true, "snippet" : true }, "name" : "WoS", "nameEng" : "WoS", "linkPattern" : "https://www.webofscience.com/wos/woscc/full-record/@@@", "publiclyVisible" : true, "published" : true, "oldId" : 1, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "000413005100009", "realUrl" : "https://www.webofscience.com/wos/woscc/full-record/000413005100009", "published" : false, "snippet" : true }, { "otype" : "PublicationIdentifier", "mtid" : 13234601, "link" : "/api/publicationidentifier/13234601", "label" : "Scopus: 85010209033", "source" : { "otype" : "PlainSource", "mtid" : 3, "link" : "/api/publicationsource/3", "label" : "Scopus", "type" : { "otype" : "PublicationSourceType", "mtid" : 10003, "link" : "/api/publicationsourcetype/10003", "label" : "Indexelő adatbázis", "mayHaveOa" : false, "published" : true, "snippet" : true }, "name" : "Scopus", "linkPattern" : "http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@", "publiclyVisible" : true, "published" : true, "oldId" : 3, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "85010209033", "realUrl" : "http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85010209033", "published" : false, "oldId" : 16042917, "snippet" : true } ], "firstPage" : "109", "lastPage" : "143", "firstPageOrInternalIdForSort" : "109", "pageLength" : 35, "publishedYear" : 2017, "digital" : null, "printed" : null, "sourceYear" : 2017, "packet" : "189439", "foreignEdition" : true, "foreignLanguage" : true, "fullPublication" : true, "conferencePublication" : false, "nationalOrigin" : false, "missingAuthor" : false, "oaType" : "NONE", "oaCheckDate" : "2024-02-27", "oaFree" : false, "citationCount" : 0, "citationCountUnpublished" : 0, "citationCountWoOther" : 0, "independentCitCountWoOther" : 0, "doiCitationCount" : 0, "wosCitationCount" : 0, "scopusCitationCount" : 0, "independentCitationCount" : 0, "unhandledCitationCount" : 0, "citingPubCount" : 0, "independentCitingPubCount" : 0, "unhandledCitingPubCount" : 0, "citedPubCount" : 1, "citedCount" : 1, "referenceList" : "Adeniji, A.O., Wells, R.M., Adejare, A., Syntheses and in-vitro evaluation of novel adamantane based gamma-secretase inhibitors (2012) Curr. Med. Chem., 19, pp. 2458-2471; \n\nAlexander, R., Budd, S., Russell, M., Kugler, A., Cebers, G., Ye, N., Olsson, T., Ereshefsky, L., AZD3293 A novel BACE1 inhibitor: safety, tolerability, and effects on plasma and CSF Aβ peptides following single- and multiple-dose administration (2014) Neurobiol. Aging, 35, p. S2; \n\nAlzheimer's, A., 2014 Alzheimer's disease facts and figures (2014) Alzheimers Dement., 10, pp. e47-92; \n\nAnderson, J.P., Esch, F.S., Keim, P.S., Sambamurti, K., Lieberburg, I., Robakis, N.K., Exact cleavage site of Alzheimer amyloid precursor in neuronal PC-12 cells (1991) Neurosci. Lett., 128, pp. 126-128; \n\nAnderson, J.J., Holtz, G., Baskin, P.P., Wang, R., Mazzarelli, L., Wagner, S.L., Menzaghi, F., Reduced cerebrospinal fluid levels of alpha-secretase-cleaved amyloid precursor protein in aged rats: correlation with spatial memory deficits (1999) Neuroscience, 93, pp. 1409-1420; \n\nBard, F., Cannon, C., Barbour, R., Burke, R.L., Games, D., Grajeda, H., Guido, T., Yednock, T., Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease (2000) Nat. Med., 6, pp. 916-919; \n\nBate, C., Williams, A., Amyloid-β1-40 inhibits amyloid-β1-42 induced activation of cytoplasmic phospholipase A2 and synapse degeneration (2010) J. Alzheimers Dis., 21, pp. 985-993; \n\nBateman, R.J., Siemers, E.R., Mawuenyega, K.G., Wen, G., Browning, K.R., Sigurdson, W.C., Yarasheski, K.E., Holtzman, D.M., A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system (2009) Ann. Neurol., 66, pp. 48-54; \n\nBateman, R.J., Xiong, C., Benzinger, T.L., Fagan, A.M., Goate, A., Fox, N.C., Marcus, D.S., Dominantly Inherited Alzheimer, Network, Clinical and biomarker changes in dominantly inherited Alzheimer's disease (2012) N. Engl. J. Med., 367, pp. 795-804; \n\nBennett, D.A., Schneider, J.A., Arvanitakis, Z., Kelly, J.F., Aggarwal, N.T., Shah, R.C., Wilson, R.S., Neuropathology of older persons without cognitive impairment from two community-based studies (2006) Neurology, 66, pp. 1837-1844; \n\nBlasko, I., Beer, R., Bigl, M., Apelt, J., Franz, G., Rudzki, D., Ransmayr, G., Schliebs, R., Experimental traumatic brain injury in rats stimulates the expression, production and activity of Alzheimer's disease beta-secretase (BACE-1) (2004) J. Neural Transm., 111, pp. 523-536; \n\nBlazer, L.L., Neubig, R.R., Small molecule protein-protein interaction inhibitors as CNS therapeutic agents: current progress and future hurdles (2008) Neuropsychopharmacology, 34, pp. 126-141; \n\nBloom, G.S., Amyloid-beta and tau: the trigger and bullet in Alzheimer disease pathogenesis (2014) JAMA Neurol., 71, pp. 505-508; \n\nBorgegard, T., Jureus, A., Olsson, F., Rosqvist, S., Sabirsh, A., Rotticci, D., Paulsen, K., Lundkvist, J., First and second generation β-secretase modulators (GSMs) modulate amyloid-β (Aβ) peptide production through different mechanisms (2012) J. Biol. Chem., 287, pp. 11810-11819; \n\nBurton, C.R., Meredith, J.E., Barten, D.M., Goldstein, M.E., Krause, C.M., Kieras, C.J., Sisk, L., Toyn, J.H., The amyloid-β rise and β-secretase inhibitor potency depend on the level of substrate expression (2008) J. Biol. Chem., 283, pp. 22992-23003; \n\nButini, S., Brogi, S., Novellino, E., Campiani, G., Ghosh, A.K., Brindisi, M., Gemma, S., The structural evolution of β-secretase inhibitors: a focus on the development of small-molecule inhibitors (2013) Curr. Top. Med. Chem., 13, pp. 1787-1807; \n\nButtini, M., Masliah, E., Barbour, R., Grajeda, H., Motter, R., Johnson-Wood, K., Khan, K., Games, D., β-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease (2005) J. Neurosci., 25, pp. 9096-9101; \n\nCai, H., Wang, Y., McCarthy, D., Wen, H., Borchelt, D.R., Price, D.L., Wong, P.C., BACE1 is the major β-secretase for generation of Aβ peptides by neurons (2001) Nat. Neurosci., 4, pp. 233-234; \n\nCastellano, J.M., Kim, J., Stewart, F.R., Jiang, H., DeMattos, R.B., Patterson, B.W., Fagan, A.M., Holtzman, D.M., Human apoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) Sci. Transl. Med., 3. , 89ra57; \n\nChartier-Harlin, M.C., Crawford, F., Houlden, H., Warren, A., Hughes, D., Fidani, L., Goate, A., Hardy, J., Early-onset Alzheimer's disease caused by mutations at codon 717 of the β-amyloid precursor protein gene (1991) Nature, 353, pp. 844-846; \n\nChavez-Gutierrez, L., Bammens, L., Benilova, I., Vandersteen, A., Benurwar, M., Borgers, M., Lismont, S., De Strooper, B., The mechanism of β-Secretase dysfunction in familial Alzheimer disease (2012) EMBO J., 31, pp. 2261-2274; \n\nChavez-Gutierrez, L., Dissecting β-secretase function (2013) J. Neurochem., 125, pp. 1-3; \n\nCheng, A.C., Coleman, R.G., Smyth, K.T., Cao, Q., Soulard, P., Caffrey, D.R., Salzberg, A.C., Huang, E.S., Structure-based maximal affinity model predicts small-molecule druggability (2007) Nat. Biotechnol., 25, pp. 71-75; \n\nCherny, R.A., Atwood, C.S., Xilinas, M.E., Gray, D.N., Jones, W.D., McLean, C.A., Barnham, K.J., Bush, A.I., Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice (2001) Neuron, 30, pp. 665-676; \n\nCohen, S.I., Linse, S., Luheshi, L.M., Hellstrand, E., White, D.A., Rajah, L., Otzen, D.E., Knowles, T.P., Proliferation of amyloid-beta42 aggregates occurs through a secondary nucleation mechanism (2013) Proc. Natl. Acad. Sci. U.S.A., 110, pp. 9758-9763; \n\nColciaghi, F., Borroni, B., Pastorino, L., Marcello, E., Zimmermann, M., Cattabeni, F., Padovani, A., Di Luca, M., β-Secretase ADAM10 as well as βAPPs is reduced in platelets and CSF of Alzheimer disease patients (2002) Mol. Med., 8, pp. 67-74; \n\nCole, D.C., Manas, E.S., Stock, J.R., Condon, J.S., Jennings, L.D., Aulabaugh, A., Chopra, R., Bard, J., Acylguanidines as small-molecule β-secretase inhibitors (2006) J. Med. Chem., 49, pp. 6158-6161; \n\nCrump, C.J., Johnson, D.S., Li, Y.M., Development and mechanism of gamma-secretase modulators for Alzheimer's disease (2013) Biochemistry, 52, pp. 3197-3216; \n\nD'Andrea, M.R., Nagele, R.G., Wang, H.Y., Peterson, P.A., Lee, D.H., Evidence that neurons accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease (2001) Histopathology, 38, pp. 120-134; \n\nDe Strooper, B., Lessons from a failed β-secretase Alzheimer trial (2014) Cell, 159, pp. 721-726; \n\nDeMattos, R.B., Bales, K.R., Cummins, D.J., Dodart, J.C., Paul, S.M., Holtzman, D.M., Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease (2001) Proc. Natl. Acad. Sci. U.S.A., 98, pp. 8850-8855; \n\nDockens, R., Wang, J.S., Castaneda, L., Sverdlov, O., Huang, S.P., Slemmon, R., Gu, H., Tong, G., A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects (2012) Clin. Pharmacokinet., 51, pp. 681-693; \n\nDoody, R.S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Semagacestat Study, Group, A phase 3 trial of semagacestat for treatment of Alzheimer's disease (2013) N. Engl. J. Med., 369, pp. 341-350; \n\nDoody, R.S., Thomas, R.G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Solanezumab Study, Group, Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease (2014) N. Engl. J. Med., 370, pp. 311-321; \n\nDovey, H.F., John, V., Anderson, J.P., Chen, L.Z., de Saint Andrieu, P., Fang, L.Y., Freedman, S.B., Audia, J.E., Functional β-secretase inhibitors reduce β-amyloid peptide levels in brain (2001) J. Neurochem., 76, pp. 173-181; \n\nDrachman, D.A., The amyloid hypothesis, time to move on: amyloid is the downstream result, not cause, of Alzheimer's disease (2014) Alzheimers Dement., 10, pp. 372-380; \n\nDrott, J., Desire, L., Drouin, D., Pando, M., Haun, F., Etazolate improves performance in a foraging and homing task in aged rats (2010) Eur. J. Pharmacol., 634, pp. 95-100; \n\nEriksen, J.L., Sagi, S.A., Smith, T.E., Weggen, S., Das, P., McLendon, D.C., Ozols, V.V., Golde, T.E., NSAIDs and enantiomers of flurbiprofen target β-secretase and lower Aβ 42 in vivo (2003) J. Clin. Invest., 112, pp. 440-449; \n\nEsch, F.S., Keim, P.S., Beattie, E.C., Blacher, R.W., Culwell, A.R., Oltersdorf, T., McClure, D., Ward, P.J., Cleavage of amyloid β peptide during constitutive processing of its precursor (1990) Science, 248, pp. 1122-1124; \n\nEsler, W.P., Kimberly, W.T., Ostaszewski, B.L., Diehl, T.S., Moore, C.L., Tsai, J.Y., Rahmati, T., Wolfe, M.S., Transition-state analogue inhibitors of β-secretase bind directly to presenilin-1 (2000) Nat. Cell Biol., 2, pp. 428-434; \n\nEvans, C.G., Wisen, S., Gestwicki, J.E., Heat shock proteins 70 and 90 inhibit early stages of amyloid β-(1-42) aggregation in vitro (2006) J. Biol. Chem., 281, pp. 33182-33191; \n\nEvin, G., Barakat, A., Masters, C.L., BACE: therapeutic target and potential biomarker for Alzheimer's disease (2010) Int. J. Biochem. Cell Biol., 42, pp. 1923-1926; \n\nFahrenholz, F., Alpha-secretase as a therapeutic target (2007) Curr. Alzheimer Res., 4, pp. 412-417; \n\nFarlow, M., Arnold, S.E., van Dyck, C.H., Aisen, P.S., Snider, B.J., Porsteinsson, A.P., Friedrich, S., Siemers, E.R., Safety and biomarker effects of solanezumab in patients with Alzheimer's disease (2012) Alzheimers Dement., 8, pp. 261-271; \n\nFernandez-Vizarra, P., Fernandez, A.P., Castro-Blanco, S., Serrano, J., Bentura, M.L., Martinez-Murillo, R., Martinez, A., Rodrigo, J., Intra- and extracellular Aβ and PHF in clinically evaluated cases of Alzheimer's disease (2004) Histol. Histopathol., 19, pp. 823-844; \n\nFleisher, A.S., Raman, R., Siemers, E.R., Becerra, L., Clark, C.M., Dean, R.A., Farlow, M.R., Thal, L.J., Phase 2 safety trial targeting amyloid β production with a β-secretase inhibitor in Alzheimer disease (2008) Arch. Neurol., 65, pp. 1031-1038; \n\nFleisher, A.S., Chen, K., Quiroz, Y.T., Jakimovich, L.J., Gomez, M.G., Langois, C.M., Langbaum, J.B., Reiman, E.M., Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study (2012) Lancet Neurol., 11, pp. 1057-1065; \n\nFonte, V., Kapulkin, W.J., Taft, A., Fluet, A., Friedman, D., Link, C.D., Interaction of intracellular β amyloid peptide with chaperone proteins (2002) Proc. Natl. Acad. Sci. U.S.A., 99, pp. 9439-9444; \n\nForman, M., Kleijn, H.-J., Dockendorf, M., Palcza, J., Tseng, J., Canales, C., Egan, M., Stone, J., The novel BACE inhibitor MK-8931 dramatically lowers CSF β-amyloid in patients with mild-to-moderate Alzheimer's disease (2013) Alzheimers Dement. J. Alzheimers Assoc., 9, p. P139; \n\nFornicola, W., Pelcovits, A., Li, B.X., Heath, J., Perry, G., Castellani, R.J., Alzheimer disease pathology in middle age reveals a spatial-temporal disconnect between amyloid-β and phosphorylated tau (2014) Open Neurol. J., 8, pp. 22-26; \n\nFradinger, E.A., Monien, B.H., Urbanc, B., Lomakin, A., Tan, M., Li, H., Spring, S.M., Bitan, G., C-terminal peptides coassemble into Aβ42 oligomers and protect neurons against Aβ42-induced neurotoxicity (2008) Proc. Natl. Acad. Sci. U.S.A., 105, pp. 14175-14180; \n\nFrautschy, S.A., Hu, W., Kim, P., Miller, S.A., Chu, T., Harris-White, M.E., Cole, G.M., Phenolic anti-inflammatory antioxidant reversal of Aβ-induced cognitive deficits and neuropathology (2001) Neurobiol. Aging, 22, pp. 993-1005; \n\nFreskos, J.N., Fobian, Y.M., Benson, T.E., Moon, J.B., Bienkowski, M.J., Brown, D.L., Emmons, T.L., Winterrowd, G., Design of potent inhibitors of human β-secretase. Part 2 (2007) Bioorg. Med. Chem. Lett., 17, pp. 78-81; \n\nFu, H.J., Liu, B., Frost, J.L., Lemere, C.A., Amyloid-β immunotherapy for Alzheimer's disease (2010) CNS Neurol. Disord. Drug Targets, 9, pp. 197-206; \n\nFuwa, H., Takahashi, Y., Konno, Y., Watanabe, N., Miyashita, H., Sasaki, M., Natsugari, H., Iwatsubo, T., Divergent synthesis of multifunctional molecular probes to elucidate the enzyme specificity of dipeptidic β-secretase inhibitors (2007) ACS Chem. Biol., 2, pp. 408-418; \n\nGames, D., Adams, D., Alessandrini, R., Barbour, R., Berthelette, P., Blackwell, C., Carr, T., Gillespie, F., Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein (1995) Nature, 373, pp. 523-527; \n\nGandy, S., The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease (2005) J. Clin. Invest., 115, pp. 1121-1129; \n\nGardberg, A.S., Dice, L.T., Ou, S., Rich, R.L., Helmbrecht, E., Ko, J., Wetzel, R., Dealwis, C., Molecular basis for passive immunotherapy of Alzheimer's disease (2007) Proc. Natl. Acad. Sci. U.S.A., 104, pp. 15659-15664; \n\nGerritz, S.W., Zhai, W., Shi, S., Zhu, S., Toyn, J.H., Meredith, J.E., Iben, L.G., Thompson, L.A., Acyl guanidine inhibitors of β-secretase (BACE-1): optimization of a micromolar hit to a nanomolar lead via iterative solid- and solution-phase library synthesis (2012) J. Med. Chem., 55, pp. 9208-9223; \n\nGhosh, A.K., Kumaragurubaran, N., Hong, L., Lei, H., Hussain, K.A., Liu, C.-F., Devasamudram, T., Tang, J., Design, synthesis and X-ray structure of proteinβligand complexes: important insight into selectivity of memapsin 2 (β-secretase) inhibitors (2006) J. Am. Chem. Soc., 128, pp. 5310-5311; \n\nGhosh, A., Gemma, S., Tang, J., β-Secretase as a therapeutic target for Alzheimer's disease (2008) Neurotherapeutics, 5, pp. 399-408; \n\nGhosh, A.K., Brindisi, M., Tang, J., Developing beta-secretase inhibitors for treatment of Alzheimer's disease (2012) J. Neurochem., 120, pp. 71-83; \n\nGilbert, E.J., 1,3-Oxazines as BACE1 and/or BACE2 inhibitors: a patent evaluation (WO2012156284) (2013) Expert Opin. Ther. Pat., 23, pp. 1069-1073; \n\nGillman, K.W., Starrett, J.E., Parker, M.F., Xie, K., Bronson, J.J., Marcin, L.R., McElhone, K.E., Olson, R.E., Discovery and evaluation of BMS-708163, a potent, selective and orally bioavailable β-secretase inhibitor (2010) ACS Med. Chem. Lett., 1, pp. 120-124; \n\nGilman, S., Koller, M., Black, R.S., Jenkins, L., Griffith, S.G., Fox, N.C., Eisner, L., Orgogozo, J.M., Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial (2005) Neurology, 64, pp. 1553-1562; \n\nGitter, B.D., Czilli, D.L., Li, W., Dieckman, D.K., Bender, M.H., Nissen, J.S., Mabry, T.E., Hyslop, P.A., P4-339 Stereoselective inhibition of amyloid β peptide secretion by LY450139, a novel functional gamma secretase inhibitor (2004) Neurobiol. Aging, 25, p. S571; \n\nGlenner, G.G., Wong, C.W., Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein (1984) Biochem. Biophys. Res. Commun., 122, pp. 1131-1135; \n\nGlenner, G.G., Wong, C.W., Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein (1984) Biochem. Biophys. Res. Commun., 120, pp. 885-890; \n\nGoate, A., Chartier-Harlin, M.C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., James, L., Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease (1991) Nature, 349, pp. 704-706; \n\nGolde, T.E., Koo, E.H., Felsenstein, K.M., Osborne, B.A., Miele, L., β-Secretase inhibitors and modulators (2013) Biochim. Biophys. Acta, 1828, pp. 2898-2907; \n\nGong, B., Vitolo, O.V., Trinchese, F., Liu, S., Shelanski, M., Arancio, O., Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment (2004) J. Clin. Invest., 114, pp. 1624-1634; \n\nGotz, J., Chen, F., van Dorpe, J., Nitsch, R.M., Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Aβ 42 fibrils (2001) Science, 293, pp. 1491-1495; \n\nGouras, G.K., Tsai, J., Naslund, J., Vincent, B., Edgar, M., Checler, F., Greenfield, J.P., Relkin, N.R., Intraneuronal Aβ42 accumulation in human brain (2000) Am. J. Pathol., 156, pp. 15-20; \n\nHaapasalo, A., Kovacs, D.M., The many substrates of presenilin/β-secretase (2011) J. Alzheimers Dis., 25, pp. 3-28; \n\nHaass, C., Selkoe, D.J., Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide (2007) Nat. Rev. Mol. Cell Biol., 8, pp. 101-112; \n\nHaass, C., Hung, A.Y., Schlossmacher, M.G., Teplow, D.B., Selkoe, D.J., β-Amyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanisms (1993) J. Biol. Chem., 268, pp. 3021-3024; \n\nHamilton, A., Zamponi, G.W., Ferguson, S.S., Glutamate receptors function as scaffolds for the regulation of β-amyloid and cellular prion protein signaling complexes (2015) Mol. Brain, 8, p. 18; \n\nHardy, J., Allsop, D., Amyloid deposition as the central event in the aetiology of Alzheimer's disease (1991) Trends Pharmacol. Sci., 12, pp. 383-388; \n\nHardy, J.A., Higgins, G.A., Alzheimer's disease: the amyloid cascade hypothesis (1992) Science, 256, pp. 184-185; \n\nHardy, J., Selkoe, D.J., The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics (2002) Science, 297, pp. 353-356; \n\nHashimoto, T., Ishibashi, A., Hagiwara, H., Murata, Y., Takenaka, O., Miyagawa, T., E2012: a novel β-secretase modulator-pharmacology part (2010) Alzheimer's Dement. J. Alzheimer's Assoc., 6, p. S242; \n\nHebert, L., (2007) American College of Neuropsychopharmacology; \n\nHenley, D.B., May, P.C., Dean, R.A., Siemers, E.R., Development of semagacestat (LY450139), a functional β-secretase inhibitor, for the treatment of Alzheimer's disease (2009) Expert Opin. Pharmacother., 10, pp. 1657-1664; \n\nHigaki, J., Quon, D., Zhong, Z., Cordell, B., Inhibition of β-amyloid formation identifies proteolytic precursors and subcellular site of catabolism (1995) Neuron, 14, pp. 651-659; \n\nHolmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R.W., Nicoll, J.A., Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial (2008) Lancet, 372, pp. 216-223; \n\nHong, L., Koelsch, G., Lin, X., Wu, S., Terzyan, S., Ghosh, A.K., Zhang, X.C., Tang, J., Structure of the protease domain of memapsin 2 (β-secretase) complexed with inhibitor (2000) Science, 290, pp. 150-153; \n\nHopkins, C.R., ACS chemical neuroscience molecule spotlight on Begacestat (GSI-953) (2012) ACS Chem. Neurosci., 3, pp. 3-4; \n\nHuang, D., Liu, Y., Shi, B., Li, Y., Wang, G., Liang, G., Comprehensive 3D-QSAR and binding mode of BACE-1 inhibitors using R-group search and molecular docking (2013) J. Mol. Graph. Model., 45, pp. 65-83; \n\nHubin, E., van Nuland, N.A., Broersen, K., Pauwels, K., Transient dynamics of Aβ contribute to toxicity in Alzheimer's disease (2014) Cell Mol. Life Sci., 71, pp. 3507-3521; \n\nHudry, E., Dashkoff, J., Roe, A.D., Takeda, S., Koffie, R.M., Hashimoto, T., Scheel, M., Hyman, B.T., Gene transfer of human Apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain (2013) Sci. Transl. Med., 5. , 212ra161; \n\nIserloh, U., Wu, Y., Cumming, J.N., Pan, J., Wang, L.Y., Stamford, A.W., Kennedy, M.E., Voigt, J., Potent pyrrolidine- and piperidine-based BACE-1 inhibitors (2008) Bioorg. Med. Chem. Lett., 18, pp. 414-417; \n\nIulita, M.F., Allard, S., Richter, L., Munter, L.M., Ducatenzeiler, A., Weise, C., Do Carmo, S., Cuello, A.C., Intracellular Aβ pathology and early cognitive impairments in a transgenic rat overexpressing human amyloid precursor protein: a multidimensional study (2014) Acta Neuropathol. Commun., 2, p. 61; \n\nJack, C.R., Knopman, D.S., Jagust, W.J., Petersen, R.C., Weiner, M.W., Aisen, P.S., Shaw, L.M., Trojanowski, J.Q., Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers (2013) Lancet Neurol., 12, pp. 207-216; \n\nJan, A., Adolfsson, O., Allaman, I., Buccarello, A.L., Magistretti, P.J., Pfeifer, A., Muhs, A., Lashuel, H.A., Aβ42 neurotoxicity is mediated by ongoing nucleated polymerization process rather than by discrete Aβ42 species (2011) J. Biol. Chem., 286, pp. 8585-8596; \n\nJia, Q., Deng, Y., Qing, H., Potential therapeutic strategies for Alzheimer's disease targeting or beyond β-amyloid: insights from clinical trials (2014) BioMed. Res. Int., 2014, p. 837157; \n\nJiang, Y., Mullaney, K.A., Peterhoff, C.M., Che, S., Schmidt, S.D., Boyer-Boiteau, A., Ginsberg, S.D., Nixon, R.A., Alzheimer's-related endosome dysfunction in Down syndrome is Aβ-independent but requires APP and is reversed by BACE-1 inhibition (2010) Proc. Natl. Acad. Sci. U.S.A., 107, pp. 1630-1635; \n\nJohnston, J.A., Liu, W.W., Todd, S.A., Coulson, D.T., Murphy, S., Irvine, G.B., Passmore, A.P., Expression and activity of β-site amyloid precursor protein cleaving enzyme in Alzheimer's disease (2005) Biochem. Soc. Trans., 33, pp. 1096-1100; \n\nJones, S., Thornton, J.M., Principles of protein-protein interactions (1996) Proc. Natl. Acad. Sci. U.S.A., 93, pp. 13-20; \n\nKang, J., Lemaire, H.G., Unterbeck, A., Salbaum, J.M., Masters, C.L., Grzeschik, K.H., Multhaup, G., Muller-Hill, B., The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor (1987) Nature, 325, pp. 733-736; \n\nKarch, C.M., Goate, A.M., Alzheimer's disease risk genes and mechanisms of disease pathogenesis (2015) Biol. Psychiatry, 77, pp. 43-51; \n\nKarran, E., Hardy, J., A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease (2014) Ann. Neurol., 76, pp. 185-205; \n\nKerchner, G.A., Boxer, A.L., Bapineuzumab (2010) Expert Opin. Biol. Ther., 10, pp. 1121-1130; \n\nKeskin, O., Gursoy, A., Ma, B., Nussinov, R., Principles of protein-protein interactions: what are the preferred ways for proteins to interactβ (2008) Chem. Rev., 108, pp. 1225-1244; \n\nKim, J.E., Lee, M., Fullerene inhibits β-amyloid peptide aggregation (2003) Biochem. Biophys. Res. Commun., 303, pp. 576-579; \n\nKim, J., Onstead, L., Randle, S., Price, R., Smithson, L., Zwizinski, C., Dickson, D.W., McGowan, E., Aβ40 inhibits amyloid deposition in vivo (2007) J. Neurosci., 27, pp. 627-633; \n\nKim, J., Castellano, J.M., Jiang, H., Basak, J.M., Parsadanian, M., Pham, V., Mason, S.M., Holtzman, D.M., Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A β clearance (2009) Neuron, 64, pp. 632-644; \n\nKim, J., Jiang, H., Park, S., Eltorai, A.E., Stewart, F.R., Yoon, H., Basak, J.M., Holtzman, D.M., Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-β amyloidosis (2011) J. Neurosci., 31, pp. 18007-18012; \n\nKim, J., Eltorai, A.E., Jiang, H., Liao, F., Verghese, P.B., Kim, J., Stewart, F.R., Holtzman, D.M., Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Aβ amyloidosis (2012) J. Exp. Med., 209, pp. 2149-2156; \n\nKimberly, W.T., Xia, W., Rahmati, T., Wolfe, M.S., Selkoe, D.J., The transmembrane aspartates in presenilin 1 and 2 are obligatory for β-secretase activity and amyloid β-protein generation (2000) J. Biol. Chem., 275, pp. 3173-3178; \n\nKimberly, W.T., LaVoie, M.J., Ostaszewski, B.L., Ye, W., Wolfe, M.S., Selkoe, D.J., β-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2 (2003) Proc. Natl. Acad. Sci. U.S.A., 100, pp. 6382-6387; \n\nKimura, T., Hamada, Y., Stochaj, M., Ikari, H., Nagamine, A., Abdel-Rahman, H., Igawa, N., Kiso, Y., Design and synthesis of potent β-secretase (BACE1) inhibitors with carboxylic acid bioisosteres (2006) Bioorg. Med. Chem. Lett., 16, pp. 2380-2386; \n\nKing, M.E., Kan, H.M., Baas, P.W., Erisir, A., Glabe, C.G., Bloom, G.S., Tau-dependent microtubule disassembly initiated by prefibrillar β-amyloid (2006) J. Cell Biol., 175, pp. 541-546; \n\nKlafki, H., Abramowski, D., Swoboda, R., Paganetti, P.A., Staufenbiel, M., The carboxyl termini of β-amyloid peptides 1-40 and 1-42 are generated by distinct β-secretase activities (1996) J. Biol. Chem., 271, pp. 28655-28659; \n\nKoffie, R.M., Meyer-Luehmann, M., Hashimoto, T., Adams, K.W., Mielke, M.L., Garcia-Alloza, M., Micheva, K.D., Spires-Jones, T.L., Oligomeric amyloid β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques (2009) Proc. Natl. Acad. Sci. U.S.A., 106, pp. 4012-4017; \n\nKrinsky-McHale, S.J., Devenny, D.A., Gu, H., Jenkins, E.C., Kittler, P., Murty, V.V., Schupf, N., Silverman, W., Successful aging in a 70-year-old man with down syndrome: a case study (2008) Intellect. Dev. Disabil., 46, pp. 215-228; \n\nKumar-Singh, S., Theuns, J., Van Broeck, B., Pirici, D., Vennekens, K., Corsmit, E., Cruts, M., Van Broeckhoven, C., Mean age-of-onset of familial Alzheimer disease caused by presenilin mutations correlates with both increased Aβ42 and decreased Aβ40 (2006) Hum. Mutat., 27, pp. 686-695; \n\nKuperstein, I., Broersen, K., Benilova, I., Rozenski, J., Jonckheere, W., Debulpaep, M., Vandersteen, A., De Strooper, B., Neurotoxicity of Alzheimer's disease Aβ peptides is induced by small changes in the Aβ42 to Aβ40 ratio (2010) EMBO J., 29, pp. 3408-3420; \n\nLadiwala, A.R., Litt, J., Kane, R.S., Aucoin, D.S., Smith, S.O., Ranjan, S., Davis, J., Tessier, P.M., Conformational differences between two amyloid beta oligomers of similar size and dissimilar toxicity (2012) J. Biol. Chem., 287, pp. 24765-24773; \n\nLanz, T.A., Himes, C.S., Pallante, G., Adams, L., Yamazaki, S., Amore, B., Merchant, K.M., The β-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester reduces A β levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice (2003) J. Pharmacol. Exp. Ther., 305, pp. 864-871; \n\nLauren, J., Gimbel, D.A., Nygaard, H.B., Gilbert, J.W., Strittmatter, S.M., Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers (2009) Nature, 457, pp. 1128-1132; \n\nLemere, C.A., Masliah, E., Can Alzheimer disease be prevented by amyloid-β immunotherapyβ (2010) Nat. Rev. Neurol., 6, pp. 108-119; \n\nLeon, W.C., Canneva, F., Partridge, V., Allard, S., Ferretti, M.T., DeWilde, A., Vercauteren, F., Cuello, A.C., A novel transgenic rat model with a full Alzheimer's-like amyloid pathology displays pre-plaque intracellular amyloid-beta-associated cognitive impairment (2010) J. Alzheimers Dis., 20, pp. 113-126; \n\nLeroy, K., Ando, K., Laporte, V., Dedecker, R., Suain, V., Authelet, M., Heraud, C., Brion, J.P., Lack of tau proteins rescues neuronal cell death and decreases amyloidogenic processing of APP in APP/PS1 mice (2012) Am. J. Pathol., 181, pp. 1928-1940; \n\nLesne, S., Koh, M.T., Kotilinek, L., Kayed, R., Glabe, C.G., Yang, A., Gallagher, M., Ashe, K.H., A specific amyloid-beta protein assembly in the brain impairs memory (2006) Nature, 440, pp. 352-357; \n\nLevy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D.M., Oshima, J., Pettingell, W.H., Yu, C.E., Wang, K., Candidate gene for the chromosome 1 familial Alzheimer's disease locus (1995) Science, 269, pp. 973-977; \n\nLeyhe, T., Andreasen, N., Simeoni, M., Reich, A., von Arnim, C.A., Tong, X., Yeo, A., Mistry, P., Modulation of β-amyloid by a single dose of GSK933776 in patients with mild Alzheimer's disease: a phase I study (2014) Alzheimer's Res. Ther., 6, p. 19; \n\nLi, Y.M., Xu, M., Lai, M.T., Huang, Q., Castro, J.L., DiMuzio-Mower, J., Harrison, T., Gardell, S.J., Photoactivated β-secretase inhibitors directed to the active site covalently label presenilin 1 (2000) Nature, 405, pp. 689-694; \n\nLiao, F., Hori, Y., Hudry, E., Bauer, A.Q., Jiang, H., Mahan, T.E., Lefton, K.B., Holtzman, D.M., Anti-ApoE antibody given after plaque onset decreases Aβ accumulation and improves brain function in a mouse model of Aβ amyloidosis (2014) J. Neurosci., 34, pp. 7281-7292; \n\nLloret, A., Badia, M.C., Giraldo, E., Ermak, G., Alonso, M.D., Pallardo, F.V., Davies, K.J., Vina, J., Amyloid-β toxicity and tau hyperphosphorylation are linked via RCAN1 in Alzheimer's disease (2011) J. Alzheimers Dis., 27, pp. 701-709; \n\nLo Conte, L., Chothia, C., Janin, J., The atomic structure of protein-protein recognition sites (1999) J. Mol. Biol., 285, pp. 2177-2198; \n\nLu, Y., Riddell, D., Hajos-Korcsok, E., Bales, K., Wood, K.M., Nolan, C.E., Robshaw, A.E., Pettersson, M., Cerebrospinal fluid amyloid-β (Aβ) as an effect biomarker for brain Aβ lowering verified by quantitative preclinical analyses (2012) J. Pharmacol. Exp. Ther., 342, pp. 366-375; \n\nLuo, Y., Bolon, B., Kahn, S., Bennett, B.D., Babu-Khan, S., Denis, P., Fan, W., Vassar, R., Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation (2001) Nat. Neurosci., 4, pp. 231-232; \n\nMaji, S.K., Ogorzalek Loo, R.R., Inayathullah, M., Spring, S.M., Vollers, S.S., Condron, M.M., Bitan, G., Teplow, D.B., Amino acid position-specific contributions to amyloid β-protein oligomerization (2009) J. Biol. Chem., 284, pp. 23580-23591; \n\nMandel, S.A., Amit, T., Weinreb, O., Reznichenko, L., Youdim, M.B., Simultaneous manipulation of multiple brain targets by green tea catechins: a potential neuroprotective strategy for Alzheimer and Parkinson diseases (2008) CNS Neurosci. Ther., 14, pp. 352-365; \n\nMarcade, M., Bourdin, J., Loiseau, N., Peillon, H., Rayer, A., Drouin, D., Schweighoffer, F., Desire, L., Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing (2008) J. Neurochem., 106, pp. 392-404; \n\nMartins, I.C., Kuperstein, I., Wilkinson, H., Maes, E., Vanbrabant, M., Jonckheere, W., Van Gelder, P., Rousseau, F., Lipids revert inert Aβ amyloid fibrils to neurotoxic protofibrils that affect learning in mice (2008) EMBO J., 27, pp. 224-233; \n\nMartone, R.L., Zhou, H., Atchison, K., Comery, T., Xu, J.Z., Huang, X., Gong, X., Jacobsen, J.S., Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein β-secretase for the treatment of Alzheimer's disease (2009) J. Pharmacol. Exp. Ther., 331, pp. 598-608; \n\nMasters, C.L., Simms, G., Weinman, N.A., Multhaup, G., McDonald, B.L., Beyreuther, K., Amyloid plaque core protein in Alzheimer disease and Down syndrome (1985) Proc. Natl. Acad. Sci. U.S.A., 82, pp. 4245-4249; \n\nMathis, C.A., Kuller, L.H., Klunk, W.E., Snitz, B.E., Price, J.C., Weissfeld, L.A., Rosario, B.L., Lopez, O.L., In vivo assessment of amyloid-β deposition in nondemented very elderly subjects (2013) Ann. Neurol., 73, pp. 751-761; \n\nMayer, S.C., Kreft, A.F., Harrison, B., Abou-Gharbia, M., Antane, M., Aschmies, S., Atchison, K., Jacobsen, J.S., Discovery of begacestat, a notch-1-sparing β-secretase inhibitor for the treatment of Alzheimer's disease (2008) J. Med. Chem.; \n\nMcLaurin, J., Cecal, R., Kierstead, M.E., Tian, X., Phinney, A.L., Manea, M., French, J.E., St George-Hyslop, P., Therapeutically effective antibodies against amyloid-β peptide target amyloid-β residues 4-10 and inhibit cytotoxicity and fibrillogenesis (2002) Nat. Med., 8, pp. 1263-1269; \n\nMcLaurin, J., Kierstead, M.E., Brown, M.E., Hawkes, C.A., Lambermon, M.H., Phinney, A.L., Darabie, A.A., St George-Hyslop, P., Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse model (2006) Nat. Med., 12, pp. 801-808; \n\nMilano, J., McKay, J., Dagenais, C., Foster-Brown, L., Pognan, F., Gadient, R., Jacobs, R.T., Ciaccio, P.J., Modulation of notch processing by β-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation (2004) Toxicol. Sci., 82, pp. 341-358; \n\nMitani, Y., Yarimizu, J., Saita, K., Uchino, H., Akashiba, H., Shitaka, Y., Ni, K., Matsuoka, N., Differential effects between β-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice (2012) J. Neurosci., 32, pp. 2037-2050; \n\nMullan, M., Crawford, F., Axelman, K., Houlden, H., Lilius, L., Winblad, B., Lannfelt, L., A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of β-amyloid (1992) Nat. Genet., 1, pp. 345-347; \n\nNakano-Ito, K., Fujikawa, Y., Hihara, T., Shinjo, H., Kotani, S., Suganuma, A., Aoki, T., Tsukidate, K., E2012-induced cataract and its predictive biomarkers (2014) Toxicol. Sci., 137, pp. 249-258; \n\nNess, D.K., Boggs, L.N., Hepburn, D.L., Gitter, B., Long, G.G., May, P.C., Piroozi, K.S., Yang, Z., P2-053 Reduced β-amyloid burden, increased C-99 concentrations and evaluation of neuropathology in the brains of PDAPP mice given LY450139 dihydrate daily by gavage for 5months (2004) Neurobiol. Aging, 25, pp. S238-S239; \n\nNie, Q., Du, X.-G., Geng, M.-Y., Small molecule inhibitors of amyloid β peptide aggregation as a potential therapeutic strategy for Alzheimer's disease (2011) Acta Pharmacol. Sin., 32, pp. 545-551; \n\nObregon, D.F., Rezai-Zadeh, K., Bai, Y., Sun, N., Hou, H., Ehrhart, J., Zeng, J., Tan, J., ADAM10 activation is required for green tea (-)-epigallocatechin-3-gallate-induced β-secretase cleavage of amyloid precursor protein (2006) J. Biol. Chem., 281, pp. 16419-16427; \n\nOliveira, J.M., Henriques, A.G., Martins, F., Rebelo, S., da Cruz e Silva, O.A., Amyloid-β modulates both AβPP and tau phosphorylation (2015) J. Alzheimers Dis.; \n\nOlson, R.E., Albright, C.F., Recent progress in the medicinal chemistry of β-secretase inhibitors (2008) Curr. Top. Med. Chem., 8, pp. 17-33; \n\nOrgogozo, J.M., Gilman, S., Dartigues, J.F., Laurent, B., Puel, M., Kirby, L.C., Jouanny, P., Hock, C., Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization (2003) Neurology, 61, pp. 46-54; \n\nPanza, F., Solfrizzi, V., Imbimbo, B.P., Giannini, M., Santamato, A., Seripa, D., Logroscino, G., Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease (2014) Expert Rev. Neurother., 14, pp. 973-986; \n\nPermanne, B., Adessi, C., Saborio, G.P., Fraga, S., Frossard, M.J., Van Dorpe, J., Dewachter, I., Soto, C., Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a β-sheet breaker peptide (2002) FASEB J., 16, pp. 860-862; \n\nPeters, C., Espinoza, M.P., Gallegos, S., Opazo, C., Aguayo, L.G., Alzheimer's Aβ interacts with cellular prion protein inducing neuronal membrane damage and synaptotoxicity (2015) Neurobiol. Aging, 36, pp. 1369-1377; \n\nPortelius, E., Van Broeck, B., Andreasson, U., Gustavsson, M.K., Mercken, M., Zetterberg, H., Borghys, H., Blennow, K., Acute effect on the Aβ isoform pattern in CSF in response to β-secretase modulator and inhibitor treatment in dogs (2010) J. Alzheimers Dis., 21, pp. 1005-1012; \n\nPostina, R., Activation of β-secretase cleavage (2012) J. Neurochem., 120, pp. 46-54; \n\nPradier, L., Cohen, C., Blanchard, V., Debeir, T., Barneoud, P., Canton, T., Menager, J., Alam, J., SAR228810: an antiprotofibrillar β-amyloid antibody designed to reduce risk of amyloid-related imaging abnormalities (ARIA) (2013) Alzheimers Dement. J. Alzheimers Assoc., 9, pp. P808-P809; \n\nPrice, J.L., McKeel, D.W., Buckles, V.D., Roe, C.M., Xiong, C., Grundman, M., Hansen, L.A., Morris, J.C., Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease (2009) Neurobiol. Aging, 30, pp. 1026-1036; \n\nRajapakse, H.A., Nantermet, P.G., Selnick, H.G., Munshi, S., McGaughey, G.B., Lindsley, S.R., Young, M.B., Vacca, J.P., Discovery of oxadiazoyl tertiary carbinamine inhibitors of β-secretase (BACE-1) (2006) J. Med. Chem., 49, pp. 7270-7273; \n\nRapoport, M., Dawson, H.N., Binder, L.I., Vitek, M.P., Ferreira, A., Tau is essential to β-amyloid-induced neurotoxicity (2002) Proc. Natl. Acad. Sci. U.S.A., 99, pp. 6364-6369; \n\nReiman, E.M., Quiroz, Y.T., Fleisher, A.S., Chen, K., Velez-Pardo, C., Jimenez-Del-Rio, M., Fagan, A.M., Lopera, F., Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study (2012) Lancet Neurol., 11, pp. 1048-1056; \n\nRezaei-Ghaleh, N., Giller, K., Becker, S., Zweckstetter, M., Effect of zinc binding on β-amyloid structure and dynamics: implications for Aβ aggregation (2011) Biophys. J., 101, pp. 1202-1211; \n\nRoberds, S.L., Anderson, J., Basi, G., Bienkowski, M.J., Branstetter, D.G., Chen, K.S., Freedman, S.B., McConlogue, L., BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics (2001) Hum. Mol. Genet., 10, pp. 1317-1324; \n\nRoberson, E.D., Scearce-Levie, K., Palop, J.J., Yan, F., Cheng, I.H., Wu, T., Gerstein, H., Mucke, L., Reducing endogenous tau ameliorates amyloid β-induced deficits in an Alzheimer's disease mouse model (2007) Science, 316, pp. 750-754; \n\nRochette, M.J., Murphy, M.P., β-secretase: substrates and inhibitors (2002) Mol. Neurobiol., 26, pp. 81-95; \n\nRogaev, E.I., Sherrington, R., Rogaeva, E.A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Tsuda, T., Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene (1995) Nature, 376, pp. 775-778; \n\nSalloway, S., Sperling, R., Gilman, S., Fox, N.C., Blennow, K., Raskind, M., Sabbagh, M., I.Bapineuzumab 201 Clinical, Trial, A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease (2009) Neurology, 73, pp. 2061-2070; \n\nSalloway, S., Sperling, R., Fox, N.C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Brashear, H.R., Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease (2014) N. Engl. J. Med., 370, pp. 322-333; \n\nSato, T., Diehl, T.S., Narayanan, S., Funamoto, S., Ihara, Y., De Strooper, B., Steiner, H., Wolfe, M.S., Active β-secretase complexes contain only one of each component (2007) J. Biol. Chem., 282, pp. 33985-33993; \n\nSchenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Seubert, P., Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse (1999) Nature, 400, pp. 173-177; \n\nSchmidt, B., Aspartic proteases involved in Alzheimer's disease (2003) Chembiochem, 4, pp. 366-378; \n\nSeiffert, D., Bradley, J.D., Rominger, C.M., Rominger, D.H., Yang, F., Meredith, J.E., Wang, Q., Zaczek, R., Presenilin-1 and -2 are molecular targets for β-secretase inhibitors (2000) J. Biol. Chem., 275, pp. 34086-34091; \n\nSelkoe, D.J., Alzheimer's disease: genes, proteins, and therapy (2001) Physiol. Rev., 81, pp. 741-766; \n\nSelkoe, D.J., Resolving controversies on the path to Alzheimer's therapeutics (2011) Nat. Med., 17, pp. 1060-1065; \n\nSennvik, K., Fastbom, J., Blomberg, M., Wahlund, L.O., Winblad, B., Benedikz, E., Levels of β- and β-secretase cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients (2000) Neurosci. Lett., 278, pp. 169-172; \n\nSeubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Swindlehurst, C., Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids (1992) Nature, 359, pp. 325-327; \n\nShankar, G.M., Li, S., Mehta, T.H., Garcia-Munoz, A., Shepardson, N.E., Smith, I., Brett, F.M., Selkoe, D.J., Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory (2008) Nat. Med., 14, pp. 837-842; \n\nShearman, M.S., Beher, D., Clarke, E.E., Lewis, H.D., Harrison, T., Hunt, P., Nadin, A., Castro, J.L., L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid beta-protein precursor gamma-secretase activity (2000) Biochemistry, 39, pp. 8698-8704; \n\nSherrington, R., Rogaev, E.I., Liang, Y., Rogaeva, E.A., Levesque, G., Ikeda, M., Chi, H., St George-Hyslop, P.H., Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease (1995) Nature, 375, pp. 754-760; \n\nShipton, O.A., Leitz, J.R., Dworzak, J., Acton, C.E., Tunbridge, E.M., Denk, F., Dawson, H.N., Vargas-Caballero, M., Tau protein is required for amyloid β-induced impairment of hippocampal long-term potentiation (2011) J. Neurosci., 31, pp. 1688-1692; \n\nSiemers, E.R., Quinn, J.F., Kaye, J., Farlow, M.R., Porsteinsson, A., Tariot, P., Zoulnouni, P., May, P.C., Effects of a β-secretase inhibitor in a randomized study of patients with Alzheimer disease (2006) Neurology, 66, pp. 602-604; \n\nSigurdsson, E.M., Permanne, B., Soto, C., Wisniewski, T., Frangione, B., In vivo reversal of amyloid-β lesions in rat brain (2000) J. Neuropathol. Exp. Neurol., 59, pp. 11-17; \n\nSmith, R.D., Hu, L., Falkner, J.A., Benson, M.L., Nerothin, J.P., Carlson, H.A., Exploring protein-ligand recognition with Binding MOAD (2006) J. Mol. Graph. Model., 24, pp. 414-425; \n\nSnitz, B.E., Weissfeld, L.A., Lopez, O.L., Kuller, L.H., Saxton, J., Singhabahu, D.M., Klunk, W.E., Dekosky, S.T., Cognitive trajectories associated with β-amyloid deposition in the oldest-old without dementia (2013) Neurology, 80, pp. 1378-1384; \n\nSommer, A.P., Bieschke, J., Friedrich, R.P., Zhu, D., Wanker, E.E., Fecht, H.J., Mereles, D., Hunstein, W., 670nm laser light and EGCG complementarily reduce amyloid-β aggregates in human neuroblastoma cells: basis for treatment of Alzheimer's diseaseβ (2012) Photomed. Laser Surg., 30, pp. 54-60; \n\nSperling, R.A., Aisen, P.S., Beckett, L.A., Bennett, D.A., Craft, S., Fagan, A.M., Iwatsubo, T., Phelps, C.H., Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease (2011) Alzheimers Dement., 7, pp. 280-292; \n\nSperling, R.A., Jack, C.R., Aisen, P.S., Testing the right target and right drug at the right stage (2011) Sci. Transl. Med., 3, p. 111cm133; \n\nSpires-Jones, T.L., Mielke, M.L., Rozkalne, A., Meyer-Luehmann, M., de Calignon, A., Bacskai, B.J., Schenk, D., Hyman, B.T., Passive immunotherapy rapidly increases structural plasticity in a mouse model of Alzheimer disease (2009) Neurobiol. Dis., 33, pp. 213-220; \n\nSquibb, B.-M., (2012) Statement on Avagacestat Development Status, , http://www.bms.com/news/features/2012/Pages/AvagacestatDevelopmentStatus.aspx; \n\nSun, X., He, G., Qing, H., Zhou, W., Dobie, F., Cai, F., Staufenbiel, M., Song, W., Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression (2006) Proc. Natl. Acad. Sci. U.S.A., 103, pp. 18727-18732; \n\nSyme, C.D., Nadal, R.C., Rigby, S.E., Viles, J.H., Copper binding to the amyloid-β (Aβ) peptide associated with Alzheimer's disease: folding, coordination geometry, pH dependence, stoichiometry, and affinity of Aβ-(1-28): insights from a range of complementary spectroscopic techniques (2004) J. Biol. Chem., 279, pp. 18169-18177; \n\nTakahashi, R.H., Milner, T.A., Li, F., Nam, E.E., Edgar, M.A., Yamaguchi, H., Beal, M.F., Gouras, G.K., Intraneuronal Alzheimer aβ42 accumulates in multivesicular bodies and is associated with synaptic pathology (2002) Am. J. Pathol., 161, pp. 1869-1879; \n\nTakahashi, R.H., Almeida, C.G., Kearney, P.F., Yu, F., Lin, M.T., Milner, T.A., Gouras, G.K., Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain (2004) J. Neurosci., 24, pp. 3592-3599; \n\nTakami, M., Nagashima, Y., Sano, Y., Ishihara, S., Morishima-Kawashima, M., Funamoto, S., Ihara, Y., β-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of β-carboxyl terminal fragment (2009) J. Neurosci., 29, pp. 13042-13052; \n\nTamagno, E., Guglielmotto, M., Aragno, M., Borghi, R., Autelli, R., Giliberto, L., Muraca, G., Tabaton, M., Oxidative stress activates a positive feedback between the β- and β-secretase cleavages of the β-amyloid precursor protein (2008) J. Neurochem., 104, pp. 683-695; \n\nTanzi, R.E., Bertram, L., Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective (2005) Cell, 120, pp. 545-555; \n\nTeichmann, S.A., Principles of protein-protein interactions (2002) Bioinformatics (Oxford, England), 18, p. S249; \n\nTian, G., Sobotka-Briner, C.D., Zysk, J., Liu, X., Birr, C., Sylvester, M.A., Edwards, P.D., Greenberg, B.D., Linear non-competitive inhibition of solubilized human β-secretase by pepstatin A methylester, L685458, sulfonamides, and benzodiazepines (2002) J. Biol. Chem., 277, pp. 31499-31505; \n\nTian, G., Ghanekar, S.V., Aharony, D., Shenvi, A.B., Jacobs, R.T., Liu, X., Greenberg, B.D., The mechanism of β-secretase: multiple inhibitor binding sites for transition state analogs and small molecule inhibitors (2003) J. Biol. Chem., 278, pp. 28968-28975; \n\nTolia, A., De Strooper, B., Structure and function of β-secretase (2009) Semin. Cell Dev. Biol., 20, pp. 211-218; \n\nTomiyama, T., Asano, S., Suwa, Y., Morita, T., Kataoka, K., Mori, H., Endo, N., Rifampicin prevents the aggregation and neurotoxicity of amyloid β protein in vitro (1994) Biochem. Biophys. Res. Commun., 204, pp. 76-83; \n\nTong, G., Wang, J.S., Sverdlov, O., Huang, S.P., Slemmon, R., Croop, R., Castaneda, L., Dockens, R.C., Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral β-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers (2012) Clin. Ther., 34, pp. 654-667; \n\nTu, S., Okamoto, S., Lipton, S.A., Xu, H., Oligomeric Aβ-induced synaptic dysfunction in Alzheimer's disease (2014) Mol. Neurodegener., 9, p. 48; \n\nTurner, R.T., Koelsch, G., Hong, L., Castenheira, P., Ghosh, A., Tang, J., Subsite specificity of memapsin 2 (β-secretase): implications for inhibitor design (2001) Biochemistry, 40, pp. 10001-10006; \n\nUm, J.W., Nygaard, H.B., Heiss, J.K., Kostylev, M.A., Stagi, M., Vortmeyer, A., Wisniewski, T., Strittmatter, S.M., Alzheimer amyloid-beta oligomer bound to postsynaptic prion protein activates Fyn to impair neurons (2012) Nat. Neurosci., 15, pp. 1227-1235; \n\nVarga, E., Juhasz, G., Bozso, Z., Penke, B., Fulop, L., Szegedi, V., Aβ(1-42) enhances neuronal excitability in the CA1 via NR2B subunit-containing NMDA receptors (2014) Neural Plast., 2014, p. 584314; \n\nVassar, R., BACE1 inhibitor drugs in clinical trials for Alzheimer's disease (2014) Alzheimers Res. Ther., 6, p. 89; \n\nVellas, B., Sol, O., Snyder, P.J., Ousset, P.J., Haddad, R., Maurin, M., Lemarie, J.C., E.H.T.Study, Group, EHT0202 in Alzheimer's disease: a 3-month, randomized, placebo-controlled, double-blind study (2011) Curr. Alzheimer Res., 8, pp. 203-212; \n\nVingtdeux, V., Marambaud, P., Identification and biology of β-secretase (2012) J. Neurochem., 120, pp. 34-45; \n\nVossel, K.A., Zhang, K., Brodbeck, J., Daub, A.C., Sharma, P., Finkbeiner, S., Cui, B., Mucke, L., Tau reduction prevents Aβ-induced defects in axonal transport (2010) Science, 330, p. 198; \n\nWalsh, D.M., Tseng, B.P., Rydel, R.E., Podlisny, M.B., Selkoe, D.J., The oligomerization of amyloid β-protein begins intracellularly in cells derived from human brain (2000) Biochemistry, 39, pp. 10831-10839; \n\nWalsh, D.M., Klyubin, I., Fadeeva, J.V., Cullen, W.K., Anwyl, R., Wolfe, M.S., Rowan, M.J., Selkoe, D.J., Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo (2002) Nature, 416, pp. 535-539; \n\nWalsh, D.M., Klyubin, I., Fadeeva, J.V., Rowan, M.J., Selkoe, D.J., Amyloid-β oligomers: their production, toxicity and therapeutic inhibition (2002) Biochem. Soc. Trans., 30, pp. 552-557; \n\nWang, R., Meschia, J.F., Cotter, R.J., Sisodia, S.S., Secretion of the β/A4 amyloid precursor protein. Identification of a cleavage site in cultured mammalian cells (1991) J. Biol. Chem., 266, pp. 16960-16964; \n\nWasmer, C., Lange, A., Van Melckebeke, H., Siemer, A.B., Riek, R., Meier, B.H., Amyloid fibrils of the HET-s(218-289) prion form a β solenoid with a triangular hydrophobic core (2008) Science (New York), 319, pp. 1523-1526; \n\nWatt, A.D., Crespi, G.A., Down, R.A., Ascher, D.B., Gunn, A., Perez, K.A., McLean, C.A., Miles, L.A., Do current therapeutic anti-Aβ antibodies for Alzheimer's disease engage the targetβ (2014) Acta Neuropathol., 127, pp. 803-810; \n\nWeggen, S., Eriksen, J.L., Das, P., Sagi, S.A., Wang, R., Pietrzik, C.U., Findlay, K.A., Koo, E.H., A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity (2001) Nature, 414, pp. 212-216; \n\nWeggen, S., Eriksen, J.L., Sagi, S.A., Pietrzik, C.U., Ozols, V., Fauq, A., Golde, T.E., Koo, E.H., Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid β 42 production by direct modulation of gamma-secretase activity (2003) J. Biol. Chem., 278, pp. 31831-31837; \n\nWeihofen, A., Lemberg, M.K., Friedmann, E., Rueeger, H., Schmitz, A., Paganetti, P., Rovelli, G., Martoglio, B., Targeting presenilin-type aspartic protease signal peptide peptidase with β-secretase inhibitors (2003) J. Biol. Chem., 278, pp. 16528-16533; \n\nWilliams, T.L., Johnson, B.R., Urbanc, B., Jenkins, A.T., Connell, S.D., Serpell, L.C., Aβ42 oligomers, but not fibrils, simultaneously bind to and cause damage to ganglioside-containing lipid membranes (2011) Biochem. J., 439, pp. 67-77; \n\nWillis, B., Martenyi, F., Dean, R., Lowe, S., Nakano, M., Monk, S., Gonzales, C., May, P., Central BACE1 inhibition by LY2886721 produces opposing effects on APP processing as reflected by cerebrospinal fluid sAPP-β and sAPP-β (2012) Alzheimers Dement. J. Alzheimers Assoc., 8, p. 95; \n\nWinblad, B., Andreasen, N., Minthon, L., Floesser, A., Imbert, G., Dumortier, T., Maguire, R.P., Graf, A., Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study (2012) Lancet Neurol., 11, pp. 597-604; \n\nWirths, O., Multhaup, G., Czech, C., Feldmann, N., Blanchard, V., Tremp, G., Beyreuther, K., Bayer, T.A., Intraneuronal APP/A β trafficking and plaque formation in β-amyloid precursor protein and presenilin-1 transgenic mice (2002) Brain Pathol., 12, pp. 275-286; \n\nWogulis, M., Wright, S., Cunningham, D., Chilcote, T., Powell, K., Rydel, R.E., Nucleation-dependent polymerization is an essential component of amyloid-mediated neuronal cell death (2005) J. Neurosci., 25, pp. 1071-1080; \n\nWolfe, M.S., Citron, M., Diehl, T.S., Xia, W., Donkor, I.O., Selkoe, D.J., A substrate-based difluoro ketone selectively inhibits Alzheimer's gamma-secretase activity (1998) J. Med. Chem., 41, pp. 6-9; \n\nWolfe, M.S., Xia, W., Ostaszewski, B.L., Diehl, T.S., Kimberly, W.T., Selkoe, D.J., Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and β-secretase activity (1999) Nature, 398, pp. 513-517; \n\nWolfe, M.S., Xia, W., Moore, C.L., Leatherwood, D.D., Ostaszewski, B., Rahmati, T., Donkor, I.O., Selkoe, D.J., Peptidomimetic probes and molecular modeling suggest that Alzheimer's β-secretase is an intramembrane-cleaving aspartyl protease (1999) Biochemistry, 38, pp. 4720-4727; \n\nWolfe, M.S., β-secretase inhibition and modulation for Alzheimer's disease (2008) Curr. Alzheimer Res., 5, pp. 158-164; \n\nWozniak, M.A., Itzhaki, R.F., Shipley, S.J., Dobson, C.B., Herpes simplex virus infection causes cellular β-amyloid accumulation and secretase upregulation (2007) Neurosci. Lett., 429, pp. 95-100; \n\nXu, H., Greengard, P., Gandy, S., Regulated formation of Golgi secretory vesicles containing Alzheimer β-amyloid precursor protein (1995) J. Biol. Chem., 270, pp. 23243-23245; \n\nXu, H., Sweeney, D., Greengard, P., Gandy, S., Metabolism of Alzheimer β-amyloid precursor protein: regulation by protein kinase A in intact cells and in a cell-free system (1996) Proc. Natl. Acad. Sci. U.S.A., 93, pp. 4081-4084; \n\nXue, S., Jia, L., Jia, J., Hypoxia and reoxygenation increased BACE1 mRNA and protein levels in human neuroblastoma SH-SY5Y cells (2006) Neurosci. Lett., 405, pp. 231-235; \n\nXue, W.F., Hellewell, A.L., Hewitt, E.W., Radford, S.E., Fibril fragmentation in amyloid assembly and cytotoxicity: when size matters (2010) Prion, 4, pp. 20-25; \n\nYang, L.B., Lindholm, K., Yan, R., Citron, M., Xia, W., Yang, X.L., Beach, T., Shen, Y., Elevated β-secretase expression and enzymatic activity detected in sporadic Alzheimer disease (2003) Nat. Med., 9, pp. 3-4; \n\nYang, H., Guan, H., Yang, M., Liu, Z., Takeuchi, S., Yanagisawa, D., Vincent, S.R., Tooyama, I., Upregulation of mitochondrial ferritin by proinflammatory cytokines: implications for a role in Alzheimer's disease (2015) J. Alzheimers Dis., 45, pp. 797-811; \n\nYin, Y.I., Bassit, B., Zhu, L., Yang, X., Wang, C., Li, Y.M., β-Secretase substrate concentration modulates the Aβ42/Aβ40 ratio: implications for Alzheimer disease (2007) J. Biol. Chem., 282, pp. 23639-23644; \n\nYuan, J., Venkatraman, S., Zheng, Y., McKeever, B.M., Dillard, L.W., Singh, S.B., Structure-based design of β-site APP cleaving enzyme 1 (BACE1) inhibitors for the treatment of Alzheimer's disease (2013) J. Med. Chem., 56, pp. 4156-4180; \n\nZempel, H., Thies, E., Mandelkow, E., Mandelkow, E.M., Aβ oligomers cause localized Ca2+ elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines (2010) J. Neurosci., 30, pp. 11938-11950; \n\nZempel, H., Luedtke, J., Kumar, Y., Biernat, J., Dawson, H., Mandelkow, E., Mandelkow, E.M., Amyloid-β oligomers induce synaptic damage via Tau-dependent microtubule severing by TTLL6 and spastin (2013) EMBO J., 32, pp. 2920-2937; \n\nZhang, Y.W., Xu, H., Molecular and cellular mechanisms for Alzheimer's disease: understanding APP metabolism (2007) Curr. Mol. Med., 7, pp. 687-696; \n\nZhang, Y., Rempel, D.L., Zhang, J., Sharma, A.K., Mirica, L.M., Gross, M.L., Pulsed hydrogen-deuterium exchange mass spectrometry probes conformational changes in amyloid β (Aβ) peptide aggregation (2013) Proc. Natl. Acad. Sci. U.S.A., 110, pp. 14604-14609; \n\nZigman, W.B., Devenny, D.A., Krinsky-McHale, S.J., Jenkins, E.C., Urv, T.K., Wegiel, J., Schupf, N., Silverman, W., Alzheimer's disease in adults with down syndrome (2008) Int. Rev. Res. Ment. Retard., 36, pp. 103-145", "hasCitationDuplums" : false, "userChangeableUntil" : "2017-11-23T07:40:45.000+0000", "publishDate" : "2017-11-21T09:35:39.000+0000", "directInstitutesForSort" : "", "ownerAuthorCount" : 6, "ownerInstituteCount" : 28, "directInstituteCount" : 0, "authorCount" : 3, "contributorCount" : 0, "book" : { "otype" : "Book", "mtid" : 30255251, "link" : "/api/publication/30255251", "label" : "Adeboye Adejare. Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders: Alzheimer's Disease. (2017) ISBN:9780128028117; 9780128028100", "core" : false, "citation" : false, "publicationPending" : false, "type" : { "otype" : "PublicationType", "mtid" : 23, "link" : "/api/publicationtype/23", "label" : "Könyv", "code" : 23, "otypeName" : "Book", "listPosition" : 3, "published" : true, "oldId" : 23, "snippet" : true }, "subType" : { "otype" : "SubType", "mtid" : 10000201, "link" : "/api/subtype/10000201", "label" : "Szakkönyv (Könyv)", "name" : "Szakkönyv", "nameEng" : "Monograph", "docType" : { "otype" : "PublicationType", "mtid" : 23, "link" : "/api/publicationtype/23", "label" : "Könyv", "code" : 23, "otypeName" : "Book", "listPosition" : 3, "published" : true, "oldId" : 23, "snippet" : true }, "listPosition" : 337, "published" : true, "oldId" : 10000201, "snippet" : true }, "category" : { "otype" : "Category", "mtid" : 1, "link" : "/api/category/1", "label" : "Tudományos", "published" : true, "oldId" : 1, "snippet" : true }, "languages" : [ { "otype" : "Language", "mtid" : 10002, "link" : "/api/language/10002", "label" : "Angol", "name" : "Angol", "nameEng" : "English", "published" : true, "oldId" : 2, "snippet" : true } ], "title" : "Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders: Alzheimer's Disease", "identifiers" : [ { "otype" : "PublicationIdentifier", "mtid" : 12031046, "link" : "/api/publicationidentifier/12031046", "label" : "ISBN: 9780128028117", "source" : { "otype" : "PlainSource", "mtid" : 122, "link" : "/api/publicationsource/122", "label" : "ISBN", "type" : { "otype" : "PublicationSourceType", "mtid" : 10002, "link" : "/api/publicationsourcetype/10002", "label" : "Egyéb", "mayHaveOa" : false, "published" : true, "snippet" : true }, "name" : "ISBN", "nameEng" : "ISBN", "linkPattern" : "https://www.worldcat.org/search?q=isbn%3A@@@", "publiclyVisible" : true, "published" : true, "oldId" : 122, "snippet" : true }, "idValue" : "9780128028117", "realUrl" : "https://www.worldcat.org/search?q=isbn%3A9780128028117", "published" : false, "snippet" : true }, { "otype" : "PublicationIdentifier", "mtid" : 25484569, "link" : "/api/publicationidentifier/25484569", "label" : "ISBN: 9780128028100", "source" : { "otype" : "PlainSource", "mtid" : 122, "link" : "/api/publicationsource/122", "label" : "ISBN", "type" : { "otype" : "PublicationSourceType", "mtid" : 10002, "link" : "/api/publicationsourcetype/10002", "label" : "Egyéb", "mayHaveOa" : false, "published" : true, "snippet" : true }, "name" : "ISBN", "nameEng" : "ISBN", "linkPattern" : "https://www.worldcat.org/search?q=isbn%3A@@@", "publiclyVisible" : true, "published" : true, "oldId" : 122, "snippet" : true }, "idValue" : "9780128028100", "realUrl" : "https://www.worldcat.org/search?q=isbn%3A9780128028100", "published" : false, "snippet" : true } ], "publishedAt" : [ { "otype" : "City", "mtid" : 10233, "link" : "/api/city/10233", "label" : "Philadelphia (PA), Amerikai Egyesült Államok", "partOf" : { "otype" : "Country", "mtid" : 10017, "link" : "/api/country/10017", "label" : "Amerikai Egyesült Államok", "published" : true, "oldId" : 13, "snippet" : true }, "published" : true, "oldId" : 354, "snippet" : true } ], "publishedYear" : 2017, "foreignEdition" : true, "foreignLanguage" : true, "fullPublication" : true, "conferencePublication" : false, "published" : true, "snippet" : true }, "hasQualityFactor" : false, "link" : "/api/publication/26974257", "label" : "Adeniji AO et al. Amyloid - Hypothesis in the Development of Therapeutic Agents for Alzheimer's Disease. (2017) Megjelent: Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders: Alzheimer's Disease pp. 109-143", "template" : "